High tolerance to apoptotic stimuli induced by serum depletion and ceramide in side-population cells: High expression of CD55 as a novel character for side-population

Experimental Cell Research

Volumn 313, Issue 9, 2007, Pages 1877-1885

  Xu, Jing Xian ^a   Morii, Eiichi ^a   Liu, Yalan ^a   Nakamichi, Naoto ^a,b   Ikeda, Jun ichiro ^a   Kimura, Hayato ^a   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; CD55; Side population

Indexed keywords

CERAMIDE; DECAY ACCELERATING FACTOR; HOE 33342; IMATINIB; PROTEIN BCL 2; VERAPAMIL;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DOSE RESPONSE; DOT HYBRIDIZATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 34247486847     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.03.006     Document Type: Article

References (37)

1. Heppner G.H. Tumor heterogeneity. Cancer Res. 44 (1984) 2259-2265
2. Hemburger A.W., and Salmon S.E. Primary bioassay of human tumor stem cells. Cell Sci. 197 (1977) 461-463
3. Bruce W.R., and Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199 (1963) 79-80
4. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (1977) 730-737
5. Lessard J., and Sauvageau G. Bmi-1 determined the proliferative capacity of normal and leukaemic stem cells. Nature 423 (2003) 255-260
6. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cell. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3983-3988
7. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
8. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
9. Collins A.T., Berry P.A., Hyde C., et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65 (2005) 10946-10951
10. O'Brien C.A., Pollett A., Gallinger S., et al. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 445 (2007) 106-110
11. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445 (2007) 111-115
12. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res. 67 (2007) 1030-1037
13. Prince M.E., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 973-978
14. Kondo T., Setoguchi T., and Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 781-786
15. Patrawala L., Calhoun T., Schneider-Broussard R., et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 65 (2005) 6207-6219
16. Diehn M., and Clarke M.F. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J. Natl. Cancer Inst. 98 (2006) 1755-1757
17. Graham S.M., Jorgensen H.G., Allan E., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
18. Holtz M.S., Slovak M.L., Zhang F., et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99 (2002) 3792-3800
19. Zhang X., Chen J., Davis B., et al. Hoechst 33342 induces apoptosis in HL-60 cells and inhibits topoisomerase I in vivo. Arch. Pathol. Lab. Med. 123 (1999) 921-927
20. Zhou S., Schuetz J.D., Bunting K.D., et al. The ABC transporter bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7 (2001) 1028-1034
21. Jonker J.W., Freeman J., Bolscher E., et al. Contribution of the ABC transporters bcrp1 and mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 23 (2005) 1059-1065
22. Spendlove I., Ramage J.M., Bradley R., et al. Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol. Immunother. 55 (2006) 987-995
23. Durrant L.G., Chapman M.A., Buckley D.J., et al. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol. Immunother. 52 (2003) 638-642
24. Terui Y., Sakurai T., Mishima Y., et al. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci. 97 (2006) 72-79
25. Loberg R.D., Day L.L., Dunn R., et al. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8 (2006) 69-78
26. Goodell M.A., Brose K., Paradis G., et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183 (1996) 1797-1806
27. Cai Z., Bettaieb A., Mahdani N.E., et al. Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity. J. Biol. Chem. 272 (1997) 6918-6926
28. Shabbits J.A., and Mayer L.D. P-glycoprotein modulated ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol. Cancer Ther. 1 (2002) 205-213
29. Jaattela M., Benedict M., Tewari M., et al. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 10 (1995) 2297-2305
30. Marchesini N., Luberto C., and Hannun Y.A. Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J. Biol. Chem. 278 (2003) 13775-13783
31. Chiba T., Kita K., Zheng Y.W., et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44 (2006) 240-251
32. Pushkareva M., Obeid L.M., and Hannun Y.A. Ceramide: an endogenous regulator of apoptosis and growth suppression. Immunol. Today 16 (1995) 294-297
33. Lin C.F., Chen C.L., Chang W.T., et al. Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. J. Biol. Chem. 280 (2005) 23758-23765
34. Zhang J., Alter N., Reed J.C., et al. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 5325-5328
35. Miyaji M., Jin Z.X., Yamaoka S., et al. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J. Exp. Med. 202 (2005) 249-259
36. Itoh M., Kitano T., Watanabe M., et al. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin. Cancer Res. 8 (2003) 415-423
37. Huang S.T., and Cidlowski J.A. Glucocorticoids inhibit serum depletion-induced apoptosis in T lymphocytes expressing Bcl-2. FASEB J. 13 (1999) 467-476